ALMIRALL, S.A. «...678910...» Page 7 out of 18 20/02/2023 06:56 ALMIRALL, S.A. Other relevant information A webcast with analysts and institutional investors FY 2022 Register number: 20498 20/02/2023 06:50 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2022 Register number: 20497 03/02/2023 13:43 ALMIRALL, S.A. On business and financial situation Almirall acquires Physiorelax® portfolio from DFT El Globo Register number: 20277 10/01/2023 17:37 ALMIRALL, S.A. Other relevant information Presentation: 41st Annual J.P. Morgan Healthcare Conference 2023 Register number: 19953 04/01/2023 11:52 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el cuarto trimestre de 2022 Register number: 19872 18/11/2022 07:53 ALMIRALL, S.A. On business and financial situation Almirall perpetually licenses Motilex® to Teofarma in Italy Register number: 19255 10/11/2022 07:58 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the third quarter of 2022 Register number: 19138 10/11/2022 07:54 ALMIRALL, S.A. On business and financial situation Almirall files Third Quarter results presentation for 2022 Register number: 19137 28/10/2022 07:50 ALMIRALL, S.A. On business and financial situation Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis Register number: 18925 04/10/2022 09:51 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el tercer trimestre de 2022 Register number: 18534 Page 7 out of 18 «...678910...»
